- Home
- CGTX vs KZIA Comparison
CGTX vs KZIA Comparison
Compare CGTX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- KZIA
- Stock Information
- Founded
- CGTX 2007
- KZIA 1994
- Country
- CGTX United States
- KZIA Australia
- Employees
- CGTX N/A
- KZIA N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- KZIA Health Care
- Exchange
- CGTX Nasdaq
- KZIA Nasdaq
- Market Cap
- CGTX 16.1M
- KZIA 18.7M
- IPO Year
- CGTX 2021
- KZIA 1999
- Fundamental
- Price
- CGTX $0.63
- KZIA $3.02
- Analyst Decision
- CGTX Strong Buy
- KZIA Strong Buy
- Analyst Count
- CGTX 6
- KZIA 1
- Target Price
- CGTX $8.30
- KZIA $20.00
- AVG Volume (30 Days)
- CGTX 20.0M
- KZIA 85.9K
- Earning Date
- CGTX 11-13-2024
- KZIA 01-03-2025
- Dividend Yield
- CGTX N/A
- KZIA N/A
- EPS Growth
- CGTX N/A
- KZIA N/A
- EPS
- CGTX N/A
- KZIA N/A
- Revenue
- CGTX N/A
- KZIA $1,655,324.00
- Revenue This Year
- CGTX N/A
- KZIA $806.89
- Revenue Next Year
- CGTX N/A
- KZIA N/A
- P/E Ratio
- CGTX N/A
- KZIA N/A
- Revenue Growth
- CGTX N/A
- KZIA 248000.00
- 52 Week Low
- CGTX $0.34
- KZIA $1.90
- 52 Week High
- CGTX $2.95
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- CGTX 69.18
- KZIA 30.94
- Support Level
- CGTX $0.43
- KZIA $2.78
- Resistance Level
- CGTX $1.29
- KZIA $4.20
- Average True Range (ATR)
- CGTX 0.10
- KZIA 0.55
- MACD
- CGTX 0.03
- KZIA -0.13
- Stochastic Oscillator
- CGTX 27.88
- KZIA 9.92
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.